Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.
2.

The regulation of patient-reported outcome claims: need for a flexible standard.

Morris LA, Miller DW.

Value Health. 2002 Jul-Aug;5(4):372-81. Review.

PMID:
12102699
[PubMed - indexed for MEDLINE]
3.

Regulation of prescription drug promotion: direct-to-consumer advertising.

Baylor-Henry M, Drezin NA.

Clin Ther. 1998;20 Suppl C:C86-95. Review.

PMID:
9915094
[PubMed - indexed for MEDLINE]
4.

Characteristics of materials distributed by drug companies. An evaluation of appropriateness.

Stryer D, Bero LA.

J Gen Intern Med. 1996 Oct;11(10):575-83. Review.

PMID:
8945688
[PubMed - indexed for MEDLINE]
5.

Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.

McNaughton-Collins M, Walker-Corkery E, Barry MJ.

J Natl Cancer Inst Monogr. 2004;(33):78-101. Review.

PMID:
15504921
[PubMed - indexed for MEDLINE]
6.

Industry guidelines, laws and regulations ignored: quality of drug advertising in medical journals.

Lankinen KS, Levola T, Marttinen K, Puumalainen I, Helin-Salmivaara A.

Pharmacoepidemiol Drug Saf. 2004 Nov;13(11):789-95. Review.

PMID:
15486957
[PubMed - indexed for MEDLINE]
7.

The FDA's regulation of health economic information.

Neumann PJ, Claxton K, Weinstein MC.

Health Aff (Millwood). 2000 Sep-Oct;19(5):129-37. Review.

PMID:
10992660
[PubMed - indexed for MEDLINE]
Free Article
8.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

PMID:
18462574
[PubMed - indexed for MEDLINE]
Free Article
9.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
10.

Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.

D√ľndar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, Bogg J, Dickson R, Walley T.

Health Technol Assess. 2004 Jun;8(24):iii-x, 1-125. Review.

PMID:
15193209
[PubMed - indexed for MEDLINE]
Free Article
11.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

PMID:
15842952
[PubMed - indexed for MEDLINE]
Free Article
12.

Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life studies.

Cashin RP, Lui P, Machado M, Hemels ME, Corey-Lisle PK, Einarson TR.

Value Health. 2008 Mar-Apr;11(2):259-71. doi: 10.1111/j.1524-4733.2007.00243.x. Review.

PMID:
18380638
[PubMed - indexed for MEDLINE]
13.

Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.

Bottomley A, Jones D, Claassens L.

Eur J Cancer. 2009 Feb;45(3):347-53. doi: 10.1016/j.ejca.2008.09.032. Epub 2008 Nov 14. Review.

PMID:
19013787
[PubMed - indexed for MEDLINE]
14.

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review.

Hummel S, Paisley S, Morgan A, Currie E, Brewer N.

Health Technol Assess. 2003;7(33):iii, ix-x, 1-157. Review.

PMID:
14609482
[PubMed - indexed for MEDLINE]
Free Article
15.

Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.

Neumann PJ.

J Clin Psychiatry. 1999;60 Suppl 3:9-14; discussion 15. Review.

PMID:
10073371
[PubMed - indexed for MEDLINE]
16.

How the US Food and Drug Administration evaluates the scientific evidence for health claims.

Ellwood KC, Trumbo PR, Kavanaugh CJ.

Nutr Rev. 2010 Feb;68(2):114-21. doi: 10.1111/j.1753-4887.2009.00267.x. Review.

PMID:
20137056
[PubMed - indexed for MEDLINE]
17.

Recommendations on health-related quality of life research to support labeling and promotional claims in the United States.

Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, Rothman M.

Qual Life Res. 2000;9(8):887-900. Review.

PMID:
11284208
[PubMed - indexed for MEDLINE]
18.
19.

Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.

Willke RJ, Burke LB, Erickson P.

Control Clin Trials. 2004 Dec;25(6):535-52. Review.

PMID:
15588741
[PubMed - indexed for MEDLINE]
20.

Interpreting patient-reported outcome results: US FDA guidance and emerging methods.

McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD.

Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):163-9. doi: 10.1586/erp.11.12. Review.

PMID:
21476818
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk